Introduction Aerie Pharmaceuticals is a company that focuses on discovering, developing, and marketing treatments for various eye diseases such as open-angle glaucoma and retinal disorders. The company offers products like Rhopressa, Roclatan, AR-13503, and AR-1105. It was established in 2005 by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone and is headquartered in Durham, NC and North Worth, TX. |
Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 6 |
Unknown | 3 |
Mechanism CTGF modulators [+4] |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date12 Mar 2019 |
Mechanism CTGF modulators [+3] |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date18 Dec 2017 |
Target |
Mechanism TRPM8 agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date06 Dec 2023 |
Sponsor / Collaborator |
Start Date01 Nov 2022 |
Sponsor / Collaborator |
Start Date18 Jul 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Latanoprost/Netarsudil dimesylate ( CTGF x NET x PTGFR x RHOK x TGFBR2 ) | Glaucoma, Open-Angle More | Approved |
Netarsudil Mesylate ( CTGF x NET x RHOK x TGFBR2 ) | Ocular Hypertension More | Approved |
Acoltremon ( TRPM8 ) | Dry Eye Syndromes More | Phase 3 |
Dexamethasone intravitreal implant(Aerie Pharmaceuticals, Inc.) ( GR ) | Retinal Diseases More | Phase 2 |
AVX-012 | Xerophthalmia More | Phase 2 |